Inozyme Pharma Inc. CEO and Chairman, Doug Treco, Ph.D., is set to participate in a fireside chat at the Bank of America Securities 2024 Health Care Conference on May 15th, 2024. The chat will take place from 6:40-7:10pm ET / 3:40-4:10pm PT and can be accessed through the Investor Relations section of Inozyme’s website under events. A replay of the event will also be available for a limited time.
Inozyme Pharma, Inc., is a clinical-stage rare disease biopharmaceutical company that focuses on developing innovative therapeutics for treating diseases affecting the vasculature, soft tissue, and skeleton. The company’s current project is an enzyme replacement therapy, INZ-701, which aims to address pathologic mineralization and intimal proliferation that can cause severe health problems. INZ-701 is being developed for the treatment of ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis.
For more information about Inozyme or its projects, visit their website at www.inozyme.com or follow them on LinkedIn, Twitter, and Facebook. Investors can contact Stefan Riley, Senior Director of IR and Corporate Communications at (857) 330-8871 or email stefan.riley@inozyme.com with any inquiries or concerns they may have. Media inquiries can be directed to Matt Pera at SmithSolve by calling (973) 886-9150 or emailing matt.pera@smithsolve.com for any questions or comments regarding this upcoming event featuring CEO Doug Treco at the Bank of America Securities 2024 Health Care Conference on May 15th, 2024 from 6:40-7:10pm ET / 3:40-4:10pm PT accessible through Inozyme’s website under events with a replay available for a limited time only